Hepatitis B and C Seroprevalence in Solid Tumors - Necessity for Screening During Chemotherapy

Oğuz, Arzu; Aykaş, Fatma; Ünal, Dilek; Karahan, Samet; Uslu, Emine; Başak, Mustafa; Karaman, Ahmet

doi:10.7314/apjcp.2014.15.3.1411

Cited by 10 publications

(8 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…This study presents a prospective assessment for the seroprevalence of HBV and HCV in patients receiving cytotoxic chemotherapy for solid tumors in a country with low endemicity of HBV and HCV. Other studies examining these factors exist but the countries assessed were high endemic [ 3 , 6 , 8 ] or intermediate endemic [ 19 – 21 ] prevalence.…”

Section: Discussionmentioning

confidence: 99%

Prevalence of hepatitis B and C and sensibility of a selective screening questionnaire in patients receiving chemotherapy for solid tumors

et al. 2015

View full text Add to dashboard Cite

BackgroundReactivation of hepatitis B or C virus can occur in patients undergoing chemotherapy. Recommendations for selective or systematic hepatitis B virus testing prior chemotherapy for solid tumors differ. The primary aim was to determine the seroprevalence of hepatitis B or C in a low endemic country. The second objective was to assess the relevance of a questionnaire on hepatitis B/C risk factors to consider a selective screening.MethodsPatients were prospectively tested for hepatitis B/C markers. HBs antigen positive patients and isolated anti-HBc positive patients with detectable viral load received antiviral preventive treatment. Patients or physicians completed the questionnaire on infection risk factors.ResultsAmong the 450 patients included, 388 were tested for all serological markers and had gastrointestinal (63.7 %), lung (31.2 %) and skin (4.6 %) cancers. The prevalence of subjects exposed to hepatitis B virus was 8.5 % (33/388). One patient tested positive for HBs antigen and received preventive treatment. Prevalence of subjects exposed to hepatitis C was 1.3 % (5/388). The questionnaire sensitivity was 45.5 %, 100 % and 50 % for detecting carriers of hepatitis B, C and one or the other, respectively.ConclusionsSeroprevalence of hepatitis B was low. Selective screening with the questionnaire was insufficiently sensitive. Systematic screening with serological tests prior to chemotherapy in patients with solid tumors is therefore relevant.Electronic supplementary materialThe online version of this article (doi:10.1186/s12885-015-2033-z) contains supplementary material, which is available to authorized users.

show abstract

Section: Discussionmentioning

confidence: 99%

Prevalence of hepatitis B and C and sensibility of a selective screening questionnaire in patients receiving chemotherapy for solid tumors

et al. 2015

View full text Add to dashboard Cite

show abstract

“…Among adults with cancer who were newly registered at The University of Texas MD Anderson Cancer Center (MD Anderson Cancer Center) from January 2004 through April 2011, the prevalence of HCV antibodies was 1.5% overall, and it was much higher in certain subtypes—eg, it was 10.6% in those who had selected solid tumors other than HCC . In some regions of Europe and Asia, HCV antibodies have been reported in up to 2.8% of patients with solid tumors and in 30% of those with hematologic malignancies …”

Section: Associations Between Hcv Infection and Cancermentioning

confidence: 99%

The oncologic burden of hepatitis C virus infection: A clinical perspective

Torres

Shigle

Hammoudi

et al. 2017

CA A Cancer J Clinicians

110

View full text Add to dashboard Cite

Chronic hepatitis C virus (HCV) infection affects millions of people worldwide and is associated with cancer. Direct-acting antivirals (DAAs) have changed HCV treatment paradigms, but little is known about management of HCV infection in patients with cancer. The substantial burden of HCV infection in patients with cancer and the inconclusive evidence regarding detection and management of HCV infection in patients with cancer prompted us to review the literature and formulate recommendations. Patients for whom HCV screening is recommended included all patients with hematological malignancies, hematopoietic cell transplant candidates or patients with hepatocellular carcinoma (HCC). There is lack of consensus-based recommendations for the identification of other cancer patients but physicians may consider screening patients belonging to groups at heightened risk of HCV infection including persons born during 1945–1965 and those at high risk for infection. Patients with evidence of HCV infection should be assessed by an expert to evaluate liver disease severity, comorbidities associated with HCV infection, and treatment opportunities. DAA therapy should be tailored on the basis of patient prognosis, type of cancer, cancer treatment plan, and hepatic and virologic parameters. HCV-infected cancer patients with cirrhosis (or even advanced fibrosis) and those at risk for liver disease progression, especially patients with HCV-associated comorbidities, should have ongoing follow-up, regardless of whether there is a sustained virologic response, to ensure timely detection and treatment of HCC. HCV infection and its treatment should not be considered contraindications to cancer treatment and should not delay the initiation of an urgent cancer therapy.

show abstract

“…Yine ülkemizden Oğuz ve arkadaşlarının solid tümörlü hastalarla yapmış olduğu çalışmada ise Hbs Ag ve Anti Hbs pozitiflik oranları sırasıyla %4,4 ve %36,8 olduğu belirlenmiştir [15].…”

Section: Discussionunclassified

The Positivity Ratios of HBsAg, Anti-HBs and Isolated Anti-HBc in Patients with Breast and Gynecologic Cancers Prior to Chemotherapy

İnci¹,

Açıkgöz²,

Kalaycı³

et al. 2018

J Clin Exp Invest

View full text Add to dashboard Cite

Kanser hastalarına uygulanan kemoterapi HBV reaktivasyonuna neden olabilmektedir. Bu çalışmada amacımız hastanemizde takip edilen ve kemoterapi alması planlanan hastalarda kemoterapi öncesi HBV infeksiyonu açısından yapılmış olan tarama sonuçlarını değerlendirmektir. Hastalar ve Yöntemler: Bu çalışmaya 01.Haziran 2015-01.Ocak 2018 tarihleri arasında S.B.Ü.Kanuni Sultan Süleyman Eğitim ve Araştırma Hastanesi medikal onkoloji polikliniğine başvuran ve kemoterapi planlanan 83 hasta alındı. Hastaların yaş, tanıları, hepatit infeksiyonu açısından HBs Ag, Anti-HBs, Anti-HBc, ve HBV DNA sonuçları retrospektif dosya tarama yöntemi ile incelenerek kaydedildi. Bulgular: Çalışmamıza dahil edilen kemoterapi planlanmış toplam 83 hastada kanser türü dağılımına bakıldığında en sık görülen kanserlerin sırasıyla meme, over olduğu belirlenmiştir. Hastalarımızda HBsAg pozitiflik oranı %3,6, Anti-HBs(+) oranı %38,6 olarak bulundu. Çalışmamızda HBsAg negatif ,Anti-HBs negatif iken anti-HBc pozitifliği tespit edilen hasta sayısı (6/83) %7,2 olduğu ve bu hastalarının hiç birinde HBV DNA pozitifliği tespit edilmemiştir. Sonuç: Sonuç olarak Kemoterapi planlanan hastalarda reaktivasyon, karaciğer yetmezliği, kemoterapiye ara verme gibi risk faktörleri de göz önüne alınarak bu hastalar HBV infeksiyonu açısından taranmalı ve konuyla ilgili ülkemizden daha fazla sayıda hastanın yer aldığı çalışmaların yapılmasının önemli olduğunu düşünmekteyiz.

show abstract

Hepatitis B and C Seroprevalence in Solid Tumors - Necessity for Screening During Chemotherapy

Cited by 10 publications

References 30 publications

Prevalence of hepatitis B and C and sensibility of a selective screening questionnaire in patients receiving chemotherapy for solid tumors

Prevalence of hepatitis B and C and sensibility of a selective screening questionnaire in patients receiving chemotherapy for solid tumors

The oncologic burden of hepatitis C virus infection: A clinical perspective

The Positivity Ratios of HBsAg, Anti-HBs and Isolated Anti-HBc in Patients with Breast and Gynecologic Cancers Prior to Chemotherapy

Contact Info

Product

Resources

About